Literature DB >> 8134726

[Experience with a screening program for gestational diabetes].

H E Tamez Pérez1, M Rodríguez Ayala, M Treviño Hernández, J Espinosa Campos, L R Salas Galindo, J Barquet Barquet, F J Páez Jiménez.   

Abstract

OBJECTIVE: To determine the prevalence of gestational diabetes (GD) in an outpatient clinic in northeastern Mexico. PATIENTS: 732 consecutive pregnant women referred for prenatal care during a two-year period. INTERVENTION AND OUTCOME MEASURE: A 100 g glucose tolerance test was performed in the patients with sampling at 1, 2 and 3 hours postchallenge. The patients were classified according to the criteria of the American Diabetes Association as normal, abnormal, and a third category of those showing a single abnormal value in the tolerance test.
RESULTS: Six percent of the women (44/732) had GD and 1.4% (10/732) had one abnormal value. A comparison group was made with a subset of 44 of the 678 women who showed a normal tolerance test. No group differences were seen in parity, and age, nor in body weight gain or changes in body mass index, the latter measured in the initial and final weeks of pregnancy. Significant differences versus the normal women were seen in the GD group for cesarean births (43% vs 30%) and in macrosomy (25% vs 7%). The group with one abnormal test showed high values in cesareans (50%) and macrosomy (10%) but did not reach significant difference with the other groups.
CONCLUSIONS: GD was higher in our study than in the only paper on GD prevalence reported in Mexico (3.9%). The higher incidence of cesareans and macrosomy in GD makes it necessary to consider therapeutic interventions in these cases.

Entities:  

Mesh:

Year:  1993        PMID: 8134726

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  1 in total

1.  Screening and management of gestational diabetes in Mexico: results from a survey of multilocation, multi-health care institution practitioners.

Authors:  Livia Dainelli; Alberto Prieto-Patron; Irma Silva-Zolezzi; Sandra G Sosa-Rubi; Salvador Espino Y Sosa; Enrique Reyes-Muñoz; Ruy Lopez-Ridaura; Patrick Detzel
Journal:  Diabetes Metab Syndr Obes       Date:  2018-04-05       Impact factor: 3.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.